close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

18.46 +0.09 (+0.49%)
Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
19 20 Next >
News headline image
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
From Singapore Economic Development Board (EDB)A*STAR
Via ACN Newswire
News headline image
Are Tech Layoffs Going to Be a Headache for Alexandria Real Estate Equities? ↗
Tech layoffs are in the news, but life sciences companies seem to be doing better. 
Via The Motley Fool
News headline image
Takeda's Dengue Vaccine Candidate Under FDA Priority Review ↗
 
Via Benzinga
News headline image
Takeda Posts Lower 1H Profit, Lifts FY22 Outlook ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 200 companies hit new 52-week lows. 
Via Benzinga
News headline image
Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids ↗
 
Via Benzinga
News headline image
Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease ↗
The company says it plans soon to present Phase 2 results and its Phase 3 study design. 
Via Investor's Business Daily
News headline image
Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved ↗
This year, the World Health Organization (WHO) announced that cancer has become the leading cause of death worldwide, with the latest data showing that nearly 10 million deaths in 2020 were the result... 
Via Benzinga
News headline image
Why Puma Biotechnology's Shares Jumped 20% on Monday ↗
It may have benefited from positive news about another company's drug candidate. 
Via The Motley Fool
News headline image
Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings ↗
 
Via Benzinga
News headline image
Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
2 Beaten-Down Dividend Stocks That Haven't Been This Cheap In More Than a Decade ↗
Is now the time to load up on these high-yielding investments? 
Via The Motley Fool
News headline image
European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday ↗
The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close. 
Via The Motley Fool
News headline image
Takeda Delivers Strong FY2022 H1 Results and Raises Full-Year Forecast
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
7 Dividend Stocks to Sell Pronto Before a Painful Downturn ↗
Investors may find many dividend stocks to sell, considering returns from the risk-free U.S. Treasury Bills often exceed their yield. 
Via InvestorPlace
News headline image
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? ↗
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
News headline image
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Earnings Scheduled For October 27, 2022 ↗
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million. 
Via Benzinga
News headline image
3 High-Yielding Dividend Stocks Near Their 52-Week Lows ↗
These stocks all pay far higher than the S&P 500 average dividend yield of 1.8%. 
Via The Motley Fool
News headline image
Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
From Takeda Pharmaceutical Company Limited
Via Business Wire
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,... 
Via FinancialNewsMedia
Topics Cannabis
News headline image
U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Strengthening Healthcare Systems to Meet Patients’ Need for Plasma-Derived Therapies
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer ↗
 
Via Benzinga
News headline image
Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewable Energy Production in the United States
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies
From Takeda Pharmaceutical Company Limited
Via Business Wire
News headline image
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing ↗
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema. 
Via Investor's Business Daily
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today